Phase III Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Trial Profile

Phase III Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2018

At a glance

  • Drugs Peficitinib (Primary) ; Etanercept
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Feb 2018 According to an Astellas Pharma media release, results will be presented at a future medical conference.
    • 08 Feb 2018 According to an Astellas Pharma media release, based on the result of this and another trial 700248319 , company intends to discuss the data with the regulatory authorities in Japan and other Asian countries to support filing NDA.
    • 08 Feb 2018 According to an Astellas Pharma media release, primary endpoint (Percentage of subjects achieving American College of Rheumatology Criteria 20 response) has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top